natgillin/translations-raw huggingface dataset:
Hvis du har taget for meget DULOXETIN BOEHRINGER INGELHEIM Kontakt omgående lægen eller apoteket, hvis du har taget mere DULOXETIN BOEHRINGER INGELHEIM, end lægen har ordineret.
If you take more DULOXETINE BOEHRINGER INGELHEIM than you should Call your doctor or pharmacist immediately if you take more than the amount of DULOXETINE BOEHRINGER INGELHEIM prescribed by your doctor.
Der er rapporteret tilfælde af overdosering af duloxetin, alene eller i kombination med andre lægemidler, i doser på 5400 mg. Der er sket dødsfald, hovedsageligt med samtidig overdosering af andre lægemidler.
Cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 5400mg were reported.
Det er en generel anbefaling, at der bør udvises forsigtighed ved behandling af ældre (se pkt.
However, caution should be exercised when treating the elderly (see section
I de kliniske 12-ugers akut fase duloxetin forsøg med patienter med diabetisk neuropatisk smerte blev der observeret en lille men statistisk signifikant stigning i faste blodglucose hos duloxetinbehandlede patienter.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetinetreated patients.
Ved ophør af behandling med DULOXETINE BOEHRINGER INGELHEIM skal dosis gradvis reduceres over en periode på mindst en til to uger for at mindske risikoen for seponeringssymptomer (se pkt.
When stopping treatment with DULOXETINE BOEHRINGER INGELHEIM the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8).
Metabolisme og ernæring Nedsat appetit
Metabolism and Nutrition Disorders Decreased
• depression, angst og stressinkontinens
• depression, anxiety and urinary incontinence.
Antacida og H2-antagonister: Samtidig administration af duloxetin med aluminium- og magnesiumholdige antacida eller med famotidin har ingen signifikant virkning på absorptionshastigheden eller absorptionsfraktionen af duloxetin efter en oral dosis på 40 mg.
Effects of other medicinal products on duloxetine Antacids and H2 antagonists: co-administration of duloxetine with aluminium- and magnesiumcontaining antacids or duloxetine with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Det anbefales at udvise forsigtighed ved administration af DULOXETINE BOEHRINGER INGELHEIM sammen med præparater, som hovedsageligt metaboliseres via CYP2D6 (risperidon, tricycliske antidepressiva [TCA'er] såsom nortriptylin, amitriptylin og imipramin), specielt hvis disse præparater har et snævert terapeutisk indeks (som f.eks. flecainid, propafenon og metoprolol).
Caution is advised if DULOXETINE BOEHRINGER INGELHEIM is co-administered with medicinal products that are predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such as flecainide, propafenone and metoprolol).
Behandling med DULOXETINE BOEHRINGER INGELHEIM bør derfor ikke kombineres med potente CYP1A2-hæmmere som fluvoxamin (se pkt.
Therefore DULOXETINE BOEHRINGER INGELHEIM should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3).
5 Sager med selvmordsforestillinger og -adfærd er blevet rapporteret under duloxetinbehandling eller tidligt efter behandlingsophør (se pkt.
5Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4)
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 8th October 2008
Almene symptomer og reaktioner på administrationsstedet Træthed
General Disorders and Administration Site Conditions Fatigue
Det aktive stof (duloxetin) i DULOXETIN BOEHRINGER INGELHEIM bruges i andre lægemidler mod andre tilstande:
The main ingredient of DULOXETINE BOEHRINGER INGELHEIM, duloxetine, is used in other medicines for other conditions:
• tænderskæren, dehydrering, varm/kold følelse, tørst, halssammensnøring eller næseblod
• grinding of teeth, feeling hot/cold, thirst, throat tightness, nose bleeds
Vigtig information om nogle af de øvrige indholdsstoffer i DULOXETIN BOEHRINGER INGELHEIM
Important information about some of the ingredients of DULOXETINE BOEHRINGER INGELHEIM
DULOXETINE BOEHRINGER INGELHEIM kan være forbundet med sedation og svimmelhed.
DULOXETINE BOEHRINGER INGELHEIM may be associated with sedation and dizziness.
I kliniske forsøg er der observeret utilsigtede hændelser ved pludselig afbrydelse af behandlingen hos ca. 45 % og 23 % af patienterne behandlet med hhv. DULOXETINE BOEHRINGER INGELHEIM og placebo.
In clinical trials adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with DULOXETINE BOEHRINGER INGELHEIM and 23% of patients taking placebo.
Samtidig brug af DULOXETINE BOEHRINGER INGELHEIM og selektive, reversible MAOhæmmere anbefales dog ikke (se pkt.
However, the concomitant use of DULOXETINE BOEHRINGER INGELHEIM with selective, reversible MAOIs is not recommended (see section 4.4).
DULOXETIN BOEHRINGER INGELHEIM er til oral brug.
DULOXETINE BOEHRINGER INGELHEIM is for oral use.
Opbevares i den originale yderemballage.
Store in the original package.
Hyponatriæmi
Hyponatremia
Sjældne bivirkninger (det sker hos mellem 1 til 10 ud af 10.000 patienter)
Rare side effects (these can affect from 1 to 10 users in 10,000 patients treated)
Der bør udvises forsigtighed ved samtidig brug af DULOXETINE BOEHRINGER INGELHEIM og antidepressiva.
Caution should be exercised when using DULOXETINE BOEHRINGER INGELHEIM in combination with antidepressants.
Overfølsomhed Anafylaktisk reaktion
Hypersensitivity disorder Anaphylactic reaction
DULOXETINE BOEHRINGER INGELHEIM må ikke anvendes sammen med potente CYP1A2 hæmmere, som fluvoxamin, ciprofloxacin og enoxacin, idet kombinationen resulterer i forhøjet plasmakoncentration af duloxetin (se pkt.
DULOXETINE BOEHRINGER INGELHEIM should not be used in combination with fluvoxamine, ciprofloxacin or enoxacine (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
• rysten eller følelsesløshed, inklusive følelsesløshed eller prikken/snurren i huden
• tremor or numbness, including numbness or tingling of the skin
• unormal menstruation med kraftig eller forlænget blødning
• abnormal periods, including heavy or prolonged periods
2 Sager med ortostatisk hypotension og synkope er blevet rapporteret - særligt i behandlingsopstarten 3 Se pkt 4.4.
2Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment.
Hvis det vurderes, at der skal iværksættes en farmakologisk antidepressiv behandling, bør DULOXETINE BOEHRINGER INGELHEIM gradvist seponeres (se pkt.
If a decision to initiate antidepressant pharmacological therapy is taken, the gradual discontinuation of DULOXETINE BOEHRINGER INGELHEIM is recommended (see Section 4.2).
2 for yderligere information om saccharose) Kapsellåg og -bund: Gelatine, natriumlaurilsulfat, titandioxid (E171), indigotin (E132), gul jernoxid (E172) (kun i 60 mg) og Edible Green Ink (30 mg) eller Edible White Ink (60 mg).
(See end of Section 2 for further information on sucrose) Capsule shell: gelatin, sodium lauryl sulphate, titanium dioxide (E171), indigo carmine (E132), iron oxide yellow (E172) (60 mg only) and edible green ink (30 mg) or edible white ink (60 mg).
Særlige patientgrupper:
Special populations:
Akut leverskade
Acute liver injury
Uønskede virkninger kan forekomme hyppigere ved samtidig brug af DULOXETINE BOEHRINGER INGELHEIM og naturlægemidler samt kosttilskud indeholdende perikon (hypericum perforatum).
Undesirable effects may be more common during concomitant use of DULOXETINE BOEHRINGER INGELHEIM and herbal preparations containing St John's wort (Hypericum perforatum).
Der ses store inter-individuelle variationer i plasmakoncentrationen af duloxetin (se pkt.
The plasma concentration of duloxetine displays large inter-individual variability (see 5.2).
Det anbefales at udvise forsigtighed, hvis DULOXETINE BOEHRINGER INGELHEIM anvendes sammen med serotonerge antidepressiva som SSRI-præparater, tricykliske præparater (f.eks. clomipramin eller amitriptylin), perikon (hypericum perforatum), venlafaxin eller triptaner, tramadol, pethidin og tryptophan.
Caution is advisable if DULOXETINE BOEHRINGER INGELHEIM is used concomitantly with serotonergic antidepressants like SSRIs, tricyclics like clomipramine or amitriptyline, St John's wort (Hypericum perforatum), venlafaxine or triptans, tramadol, pethidine and tryptophan.
DULOXETIN BOEHRINGER INGELHEIM findes i 2 styrker: 30 og 60 mg.
DULOXETINE BOEHRINGER INGELHEIM is available in two strengths: 30 and 60 mg.
A. FREMSTILLER(E) ANSVARLIG(E) FOR BATCHFRIGIVELSE
A MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Opkastning Dyspepsi Flatulens
Constipation Diarrhoea Vomiting Dyspepsia Flatulence
De mest almindelige bivirkninger er svimmelhed, sensoriske forstyrrelser (inklusive paræstesi), søvnforstyrrelser (inklusive søvnløshed og intense drømme), opstemthed eller angst, kvalme og/eller opkastning, rysten, hovedpine, irritabilitet, diaré, hyperhidrosis og vertigo.
Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor ,headache, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported reactions.
DULOXETIN BOEHRINGER INGELHEIM bør normalt ikke bruges til behandling af børn og unge under 18 år.
Use in children and adolescents under 18 years of age DULOXETINE BOEHRINGER INGELHEIM should normally not be used for children and adolescents under 18 years.
Gastroenteritis Opstød
Gastroenteritis Eructation Gastritis
Eftersom sikkerheden af duloxetin hos spædbørn ikke er kendt, frarådes behandling med DULOXETINE BOEHRINGER INGELHEIM i den periode der ammes.
As the safety of duloxetine in infants is not known, the use of DULOXETINE BOEHRINGER INGELHEIM while breast-feeding is not recommended.
Ikke almindelige bivirkninger (det sker hos mellem 1 til 10 ud af 1.000 patienter)
Uncommon side effects (these can affect from 1 to 10 users in 1,000 patients treated)
4.2 og 4.4).
3See section 4.4
Hallucinationer Aggression og vrede4
Mania Hallucinations anger4
• frisk rødt blod i afføringen, opkastning af blod og sort tjærefarvet afføring
• passing bright red blood in your stools, vomiting blood, or black tarry stools (faeces)
Hyperglykæmi (især rapporteret hos diabetikere)
(reported especially in diabetic patients)
beruselsesfornemmelse, feber, tendens til at svede eller muskelstivhed), kramper eller stivhed
feeling of being drunk, fever, sweating or rigid muscles)
Hjælpestof: Saccharose 8,6 mg
Excipients: sucrose 17.2 mg.
Oplever du uventede virkninger, mens du tager en af disse typer medicin sammen med DULOXETIN BOEHRINGER INGELHEIM, skal du kontakte din læge.
These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with DULOXETINE BOEHRINGER INGELHEIM, you should see your doctor.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheim am Rhein, Tyskland.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheim am Rhein, Germany.
Knogler, led, muskler og bindevæv Musculoskeletale smerter
Musculoskeletal and connective tissue disorders Musculoskeletal pain
DULOXETINE BOEHRINGER INGELHEIM bør ikke bruges til patienter med svært nedsat nyrefunktion (kreatinin-clearance < 30 ml/min; se pkt.
DULOXETINE BOEHRINGER INGELHEIM should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min; see section 4.3).
INFORMATION I BRAILLE-SKRIFT DULOXETINE BOEHRINGER INGELHEIM 30 mg
INFORMATION IN BRAILLE DULOXETINE BOEHRINGER INGELHEIM 30 mg
Edible White Ink: Titandioxid (E171), propylenglycol, shellac og povidon.
Edible White Ink: titanium dioxide (E171), propylene glycol, shellac, povidone.
For patienter med ukontrolleret hypertension, er der kontraindikation for opstart af behandling med DULOXETINE BOEHRINGER INGELHEIM, da det kan udsætte patienterne for en potentiel risiko for hypertensive kriser (se pkt.
The initiation of treatment with DULOXETINE BOEHRINGER INGELHEIM is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 4.8).
Dette er baseret på et forsøg med 6 mælkeproducerende patienter, der ikke ammede deres børn.
Duloxetine is very weakly excreted into human milk based on a study of 6 lactating patients, who did not breast feed their children .
INFORMATION I BRAILLE-SKRIFT DULOXETINE BOEHRINGER INGELHEIM 60 mg
INFORMATION IN BRAILLE DULOXETINE BOEHRINGER INGELHEIM 60 mg
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheim am Rhein, Tyskland.
MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheim am Rhein, Germany.
• diarré forstoppelse, opkastning, halsbrand eller luft i maven, mavesmerter
• diarrhoea, constipation, being sick (vomiting), heartburn, breaking wind, stomach pain
DULOXETIN BOEHRINGER INGELHEIM kan gøre dig søvnig og svimmel.
DULOXETINE BOEHRINGER INGELHEIM may make you feel sleepy of dizzy.
- tidligere har haft krampeanfald - tidligere har haft mani - lider af bipolar sygdom - har øjenproblemer, såsom visse typer af grøn stær (glaukom - forøget tryk i øjet) - tidligere har lidt af blødningsforstyrrelser (tendens til blå mærker) - har risiko for at få lavt indhold af natrium i blodet.
- are taking other medicines to treat depression(see ‘Taking other medicines') - are taking St. John's Wort, a herbal treatment (Hypericum perforatum) - have kidney disease - have had seizures (fits) - have had mania - suffer from bipolar disorder - have eye problems, such as certain kinds of glaucoma (increased pressure in the eye) - have a history of bleeding disorders (tendency to develop bruises) - are at risk of low sodium levels - are currently being treated with another medicine which may cause liver damage - are taking other medicines containing duloxetine - have intolerance to some sugars (see end of Section 2) - are considering stopping DULOXETINE BOEHRINGER INGELHEIM (see section 3)
Indehaver af markedsføringstilladelsen og fremstiller Indehaver af markedsføringstilladelsen: Boehringer Ingelheim International GmbH, Binger Str. 173 D55216 Ingelheim am Rhein, Tyskland.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Boehringer Ingelheim International GmbH, Binger Str. 173 D-55216 Ingelheim am Rhein, Germany.
Edible Green Ink: Syntetisk sort jernoxid (E172), syntetisk gul jernoxid (E172), propylenglycol og shellac.
Edible green ink: black iron oxide-synthetic (E172), yellow iron oxide- synthetic (E172), propylene glycol, shellac.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver kapsel indeholder 60 mg duloxetin (som hydrochlorid).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of duloxetine (as hydrochloride).
• muskelsmerter, muskelstivhed eller muskelkramper
• muscle pain, muscle tightness, muscle spasm
• krampeanfald
• throat inflammation
Luftveje, thorax og mediastinum Gaben
Vertigo Ear pain Respiratory, thoracic and mediastinal disorders Yawning
• ændret smagsoplevelse, koncentrationsbesvær, spasmer og ufrivillige bevægelser af musklerne,
• tasting things differently than usual, disturbance in attention, stiffness, spasms and involuntary movements of the muscles, muscle twitching, abnormal manner of walking
Du bedes henvende dig til din læge, hvis din læge har udskrevet DULOXETIN BOEHRINGER INGELHEIM til en patient under 18 år, og du gerne vil diskutere dette.
If your doctor has prescribed DULOXETINE BOEHRINGER INGELHEIM for a patient under 18 and you want to discuss this, please go back to your doctor.
Almindelige bivirkninger (det sker hos mellem 1 til 10 ud af 100 patienter)
Very common side effects (these can affect more than 10 in 100 patients treated)
MINDSTEKRAV TIL MÆRKNING PÅ BLISTERKORT ELLER BLISTERSTRIPS 60 MG HÅRDE ENTEROKAPSLER
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 60 mg hard gastro-resistant capsules
Triethylcitrat.
Hypromellose.
DULOXETINE BOEHRINGER INGELHEIM 30 mg findes i pakninger med 7, 28 og 98 kapsler.
DULOXETINE BOEHRINGER INGELHEIM 30 mg is available in packs of 7, 28 and 98 capsules.
StevensJohnsons syndrom
Angio-neurotic oedema StevensJohnson Syndrome
Svært nedsat nyrefunktion (kreatinin-clearance < 30 ml/min.).
Severe renal impairment (creatinine clearance <30 ml/min) (see section 4.4).
DULOXETINE BOEHRINGER INGELHEIM 60 mg findes i pakninger med 28 og 98 kapsler.
DULOXETINE BOEHRINGER INGELHEIM 60 mg is available in packs of 28 and 98 capsules.
Hver DULOXETIN BOEHRINGER INGELHEIM-kapsel indeholder pellets af det aktive stof med en belægning, som beskytter dem mod mavesyre.
What DULOXETINE BOEHRINGER INGELHEIM looks like and contents of the pack DULOXETINE BOEHRINGER INGELHEIM is a hard gastro-resistant capsule Each capsule of DULOXETINE BOEHRINGER INGELHEIM contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN Boehringer Ingelheim UDLØBSDATO EXP {MM/ÅÅÅÅ}
NAME OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim
DULOXETINE BOEHRINGER INGELHEIM må ikke anvendes sammen med ikke-selektive, irreversible monoaminoxidase-hæmmere - MAO-hæmmere (se pkt.
Concomitant use of DULOXETINE BOEHRINGER INGELHEIM with nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs) is contraindicated (see section 4.5).
• svimmelhed og ørepine
Mania and seizures
30 mg kapslerne har mat hvid bund med påskriften "30 mg" og mat blå top med påskriften "9543".
The 30 mg capsules has an opaque white body, imprinted with ‘30 mg' and an opaque blue cap, imprinted with ‘9543'.
Nedsat nyrefunktion: Patienter med terminal nyresygdom i dialysebehandling havde et dobbelt så højt duloxetin-Cmaks.
Renal impairment: end stage renal disease (ESRD) patients receiving dialysis had 2-fold higher duloxetine Cmax and AUC values compared with healthy subjects.
60 mg kapslerne har mat grøn bund med påskriften "60 mg" og mat blå top med påskriften "9542".
The 60 mg capsules has an opaque green body, imprinted with ‘60 mg' and an opaque blue cap, imprinted with ‘9542'.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/08/471/003-005
MARKETING AUTHORISATION NUMBER(S) EU/1/08/471/003-005
DULOXETINE BOEHRINGER INGELHEIM bør ikke gives til patienter med nedsat leverfunktion på grund af leversygdom (se pkt.
DULOXETINE BOEHRINGER INGELHEIM should not be used in patients with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).
Den anbefalede dosis af DULOXETIN BOEHRINGER INGELHEIM er 1 kapsel (60 mg) én gang daglig.
The usual dose of DULOXETINE BOEHRINGER INGELHEIM is 1 capsule (60 mg) once a day, but your doctor will prescribe the dose that is right for you.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE DULOXETIN BOEHRINGER INGELHEIM
BEFORE YOU TAKE DULOXETINE BOEHRINGER INGELHEIM
Letargi Smags
Hepatic impairment
• svimmelhed, prikkende følelse som når noget sover, søvnforstyrrelse (livagtige drømme, mareridt, søvnløshed), rastløshed eller uro, angst, kvalme eller opkastning, rystelser, hovedpine, irritation, diaré, forøget tendens til at svede eller svimmelhed.
inability to sleep), feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), tremor (shakiness), headaches, feeling irritable, diarrhoea, excessive sweating or vertigo.
• nedsat aktivitet af skjoldbruskkirtlen
• decreased thyroid gland activity
LÆGEMIDDELFORM OG INDHOLDSMÆNGDE (PAKNINGSSTØRRELSE) 28 hårde enterokapsler
PHARMACEUTICAL FORM AND CONTENTS 7 hard gastro-resistant capsules, 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/08/471/011-012
MARKETING AUTHORISATION NUMBER(S) EU/1/08/471/011-012
Besværet vandladning Natlig vandladning Nedsat urinmængde
Urinary Retention Dysuria Urinary hesitation Nocturia Polyuria Urine flow decreased
Palpitationer
Agitation
Du må ikke tage mere DULOXETIN BOEHRINGER INGELHEIM pr. dag, end lægen har ordineret.
Do not take more than the daily amount of DULOXETINE BOEHRINGER INGELHEIM that has been prescribed for you in one day.
Hos de patienter, som responderede på 8-ugers akut behandling med 60 mg ARICLAIM en gang daglig i et open-label, langtids, ukontrolleret forsøg, holdt smertereduktionen i yderligere 6 måneder.
In an open label long-term uncontrolled study, the pain reduction in patients responding to 8-weeks of acute treatment of DULOXETINE BOEHRINGER INGELHEIM 60 mg once daily was maintained for a further 6-months as measured by change on the Brief Pain Inventory(BPI) 24-hour average pain item.
Man bør ikke reducere dosis ved behandling af ældre patienter udelukkende på grund af alder. Der bør dog udvises forsigtighed ved behandling af ældre (se pkt.
No dosage adjustment is recommended for elderly patients solely on the basis of age.
• sammentrækning af kæbemusklen
• contraction of the jaw muscle
Monoaminoxidasehæmmere (MAO-hæmmere): Du må ikke tage DULOXETIN BOEHRINGER INGELHEIM sammen med en MAO-hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO-hæmmer.
Monoamine Oxidase Inhibitors (MAOIs): You should not take DULOXETINE BOEHRINGER INGELHEIM if you are taking, or have recently taken within the last 14 days, another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
• unormal urinlugt
• having abnormal urine odour
30 mg: Gelatine, natriumlaurilsulfat, titandioxid (E171), indigotin (E132) og Edible Green Ink.
Sodium Lauryl Sulfate Titanium Dioxide (E171) Indigo Carmine (E132) Edible Green Ink
(monoaminoxidasehæmmer) (se afsnittet nedenfor: "Brug af anden medicin") - tager fluvoxamin (til behandling af bl.a. depression), ciprofloxacin eller enoxacin (til behandling af infektioner)
− are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or enoxacine which are used to treat some infections
Psykiske forstyrrelser Søvnløshed Uro
Psychiatric Disorders Insomnia
• øget tendens til at gabe • nedsat appetit, vægttab
• lack of appetite, weight loss
Hvis du skal tage DULOXETINE BOEHRINGER INGELHEIM, vil din læge sige det til dig.
Always take DULOXETINE BOEHRINGER INGELHEIM exactly as your doctor has told you.
DULOXETINE BOEHRINGER INGELHEIM enterokapsler indeholder saccharose.
DULOXETINE BOEHRINGER INGELHEIM contains sucrose.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 30 mg duloxetin (som hydrochlorid).
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 30 mg of duloxetine (as hydrochloride)
DULOXETIN BOEHRINGER INGELHEIM indeholder: - Aktivt stof:
What DULOXETINE BOEHRINGER INGELHEIM contains The active substance is duloxetine.
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt her.
It may harm them, even if their symptoms are the same as yours - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Edible Green Ink indeholder: Syntetisk sort jernoxid (E172), syntetisk gul jernoxid (E172), propylenglycol og Shellac.
Edible Green Ink contains: Black Iron Oxide-Synthetic (E172) Yellow Iron Oxide- Synthetic (E172) Propylene glycol
Mydriasis Synsforstyrrelser
Blurred vision Mydriasis Visual disturbance
Kuldegysninger Generel utilpashed Varmefølelse Gangforstyrrelser
Feeling hot Gait disturbance
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 60 mg duloxetin (som hydrochlorid).
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 60 mg of duloxetine (as hydrochloride)